Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS

Launched by ULTRAGENYX PHARMACEUTICAL INC · Sep 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called GTX-102 for children diagnosed with Angelman Syndrome (AS), a genetic condition that affects cognitive function and movement. The main goal of the study is to see how well GTX-102 can help improve thinking skills in children with AS. The trial is currently recruiting participants aged between 4 and 17 years old, and it is open to all genders. To be eligible, children must have a confirmed diagnosis of AS caused by a specific genetic change, be able to walk independently or with some help, and have parents or guardians who can give consent.

Participants in the study will need to attend regular visits and follow a treatment plan, which includes receiving GTX-102 and some medical tests. It's important for families to know that there are certain criteria that could exclude a child from participating, such as recent changes in medications, specific health conditions, or being pregnant or breastfeeding. The trial will also involve a procedure called a lumbar puncture (LP), which is necessary for administering the treatment. Overall, the study aims to gather valuable information on the safety and effectiveness of GTX-102 in helping children with Angelman Syndrome.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Signed informed consent from parent(s) or legal guardian(s)
• • Confirmed diagnosis of AS with genetic confirmation of full maternal ubiquitin-protein ligase E3A (UBE3A) gene deletion causing AS in the region of 15q11.2 q13
• • Able to ambulate independently, or with assistance at the Screening Visit (note, a child whose primary means of mobility is by wheelchair is excluded from the study)
• • Platelet count, prothrombin time / international normalized ratio, and partial thromboplastin time within 1.5x the normal limits at the Screening Visit
• • Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, and all study procedures, including LP procedure, MRI, and tolerating anesthesia without intubation
• • From the time of informed consent through to at least 6 months after the final dose of GTX-102, females of childbearing potential who are sexually active must use highly effective contraception or abstinence. Males are able to participate if they agree to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the study and for at least 3 months after the final dose of GTX-102
• Key Exclusion Criteria:
• • Any change in medications or diet/supplements intended to treat symptoms of AS (eg, sleeping aids, antiseizure medications, supplements, dietary change including ketogenic or low-glycemic index diet, other) within the month prior to the Screening Visit (excluding weight-based adjustments)
• • Any condition that creates an increased risk of unsuccessful LP
• • Current or expected concomitant use of drugs that increase the risk of bleeding (eg, heparin, low molecular weight heparin, platelet inhibitors)
• • Known hypersensitivity to GTX-102 or its excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
• • Presence or history of any condition, lab abnormality, or infection, that, in the judgement of the Investigator, would interfere with participation, pose undue safety risk, or would confound interpretation of results
• • Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
• • Use of any investigational product or investigational medical device within 6 months or 5 half-lives prior to the Screening Visit or any prior use of gene therapy or ASO regardless of duration since last administration
• • Concurrent participation in any interventional study